Sam Altman and Lachy Groom led a $156m series C funding round in TrialSpark, a tech-driven pharma company, with participation from Sequoia Capital, Thrive Capital, Casdin Capital, Dragoneer, Section 32, John Doerr, Spark Capital, Felicis Ventures, Sound Ventures and Arrowmark. "Trialspark is building a new type of pharma company that has the potential to dramatically expand patient access to new treatments and align key stakeholders in drug development. We are excited to be on this consequential and ambitious journey with them," Kareem Zaki, Thrive Capital General Partner.